This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

7 Big-Pharma Stocks With Untapped Potential

Stocks in this article: BMY GSX JNJ AZN ABT BAYRY SNY

3. GlaxoSmithKline (GSK)

Company profile: GlaxoSmithKline, with a market value of $115 billion, is one of the world's largest pharmaceuticals companies. Its dividend growth prospects and steady cash flow are relatively secure, given its huge list of patent-protected drugs. Its shares have yielded at least 4% annually since 2007.

Dividend Yield: 5.21%

Investor takeaway: Its shares are up 6.8% this year and have a three-year, average annual return of 11%. Analysts give its shares five "buy" ratings, four "holds," and one "weak hold," according to a survey of analysts by S&P.

S&P has it rated "sell" on valuation concerns given the ratings firm's outlook for slow sales over the next few years. Analysts' consensus estimate is for earnings of $3.75 per share this year and $4.08 per share next year, or 9% growth. About 17% of its sales come from emerging markets and "Glaxo is one of the best-positioned pharmaceutical companies in emerging markets, which should help drive growth over the long term," says Morningstar's Conover. "We project the company will grow sales in emerging markets at 8% annually from 2011 to 2015."

2. Bristol-Myers Squibb (BMY)

Company profile: Bristol-Myers Squibb, with a market value of $53 billion, is one of the world's largest branded drug developers, with pharmaceuticals for cardiovascular and infectious diseases, cancer and psychiatric disorders. Foreign operations accounted for 35% of sales last year with emerging markets making up only 8% but has a long-term goal of 15%.

Dividend Yield: 4.2%

Investor takeaway: Its shares are down 7% this year, but over the past three years, its shares have an average annual return of 18%. Analysts give its shares six "buy" ratings, two "buy/holds," nine "holds," one "weak hold," and two "sells," according to a survey of analysts by S&P. Those same analysts expect it will earn $1.93 per share this year and decline by 4% to $1.86 in 2013.

1. Johnson & Johnson (JNJ)

Company profile: Johnson & Johnson, with a market value of $189 billion, ranks as the world's biggest and most diverse health-care companies. It has three divisions: pharmaceuticals, medical devices and diagnostics, and consumer products. International sales accounted for about 56% of 2011 revenue. Morningstar's Conover said the company "has one of the lowest exposures to the emerging markets out of the entire Big Pharma group, but is slowly embracing the idea" and making foreign acquisitions. "We estimate Johnson & Johnson's emerging-market sales contribution to hit 13% in 2015 from 10% currently," he said.

Dividend Yield: 3.55%

Investor takeaway: Its shares are up 6.5% this year and 7.4% annually over three years. Analysts give its shares 10 "buys," five "buy holds," and 10" holds, according to S&P.

S&P has it rated "buy," with a $75 price target, which is a 9% premium to its current price. Analysts' consensus estimate is for earnings of $5.07 per share this year, rising to $5.47 in 2013, or 8% growth.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs